Table 1.
Comparison of clinicopathologic features between K19-proficient and deficient HCC
| Variable | All (n = 125) | K19-deficient HCC (n = 96) | K19-proficient HCC (n = 29) | p value1 |
|---|---|---|---|---|
| Age (mean ± SD), years | 65.1 (9.9) | 66.2 (8.76) | 61.3 (12.6) | 0.020 |
| Sex, n (%) | 0.027 | |||
| Female | 31 (25) | 19 (20) | 12 (41) | |
| Male | 94 (75) | 77 (80) | 17 (59) | |
| ECOG performance status, n (%) | 1.0 | |||
| 0 | 114 (91) | 87 (91) | 27 (93) | |
| 1–2 | 11 (9) | 9 (9) | 2 (7) | |
| HCV antibody, n (%) | 0.67 | |||
| Positive | 61 (50) | 48 (52) | 13 (46) | |
| Negative | 60 (50) | 45 (48) | 15 (54) | |
| Missing | 4 | 3 | 1 | |
| HBs antigen, n (%) | 0.33 | |||
| Positive | 32 (27) | 22 (24) | 10 (36) | |
| Negative | 86 (73) | 68 (76) | 18 (64) | |
| Missing | 7 | 6 | 1 | |
| AST, n (%) | 0.24 | |||
| ≥60 IU/L | 37 (31) | 26 (28) | 11 (41) | |
| <60 IU/L | 84 (69) | 68 (72) | 16 (59) | |
| Missing | 4 | 2 | 2 | |
| Total bilirubin, n (%) | 0.11 | |||
| ≥1.5 mg/dL | 9 (7) | 5 (5) | 4 (15) | |
| <1.5 mg/dL | 112 (93) | 89 (95) | 23 (85) | |
| Missing | 4 | 2 | 2 | |
| α-Fetoprotein, n (%) | 0.021 | |||
| ≥1,000 ng/mL | 14 (12) | 7 (8) | 7 (26) | |
| <1,000 ng/mL | 100 (88) | 80 (92) | 20 (74) | |
| Missing | 11 | 9 | 2 | |
| PIVKA-II, n (%) | 0.51 | |||
| ≥200 mAU/mL | 52 (46) | 38 (44) | 14 (52) | |
| <200 mAU/mL | 62 (54) | 49 (56) | 13 (48) | |
| Missing | 11 | 9 | 2 | |
| TNM stage, n (%) | 0.31 | |||
| I | 71 (57) | 58 (60) | 13 (45) | |
| II | 42 (34) | 30 (31) | 12 (41) | |
| IIIA | 12 (10) | 8 (8) | 4 (14) | |
| Tumor size, n (%) | 0.10 | |||
| ≥5 cm | 35 (28) | 23 (24) | 12 (41) | |
| <5 cm | 90 (72) | 73 (76) | 17 (59) | |
| Number of tumor, n (%) | 0.81 | |||
| Multiple | 31 (25) | 23 (24) | 8 (28) | |
| Single | 94 (75) | 73 (76) | 21 (72) | |
| Histology, n (%) | 0.11 | |||
| Poorly | 15 (12) | 9 (9) | 6 (21) | |
| Well/moderately | 110 (88) | 87 (91) | 23 (79) | |
| Microvascular invasion, n (%) | 0.019 | |||
| Present | 37 (30) | 23 (24) | 14 (48) | |
| Absent | 88 (70) | 73 (76) | 15 (52) | |
| Fibrosis stage2, n (%) | 1.0 | |||
| F0–3 | 85 (68) | 65 (68) | 20 (69) | |
| F4 | 40 (32) | 31 (32) | 9 (31) |
SD, standard deviation; HCV, hepatitis C virus; HBs, hepatitis B surface; AFP, α-fetoprotein.
1
ANOVA or Fisher's exact test.
2
New Inuyama classification which assesses the degree of fibrosis ranging from F0 (no fibrosis) to F4 (cirrhosis).